Mélina Deban, Julien Châtelain, François Fasquelle, Daniel Clerc, Laura Toussaint, Martin Hübner, Hugo Teixeira Farinha
{"title":"细胞学在腹膜癌患者接受加压腹腔喷雾化疗(PIPAC)治疗中的作用。","authors":"Mélina Deban, Julien Châtelain, François Fasquelle, Daniel Clerc, Laura Toussaint, Martin Hübner, Hugo Teixeira Farinha","doi":"10.1515/pp-2022-0197","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Cytology of ascites or peritoneal washing is a routine part of staging of peritoneal metastases (PM). We aim to determine value of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC).</p><p><strong>Methods: </strong>Single-center retrospective cohort study included consecutive patients having PIPAC for PM of different primary between January 2015 and January 2020.</p><p><strong>Results: </strong>A total of 75 patients (median 63 years (IQR 51-70), 67 % female) underwent a total of 144 PIPAC. At PIPAC 1 59 % patients had positive and 41 % patients had negative cytology. Patients with negative and positive cytology only differed in terms of symptoms of ascites (16% vs. 39 % respectively, p=0.04), median ascites volume (100 vs. 0 mL, p=0.01) and median PCI (9 vs. 19, p<0.01). Among 20 patients who completed 3 PIPACs (per protocol), cytology changed in one from positive to negative, and in two from negative to positive. Median overall survival was 30.9 months in the per protocol group and 12.9 months in patients having <3 PIPACs (=0.519).</p><p><strong>Conclusions: </strong>Positive cytology under PIPAC treatment is more frequently encountered in patients with higher PCI and symptomatic ascites. Cytoversion was rarely observed and cytology status had no impact on treatment decisions in this cohort.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249751/pdf/","citationCount":"0","resultStr":"{\"title\":\"The role of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis.\",\"authors\":\"Mélina Deban, Julien Châtelain, François Fasquelle, Daniel Clerc, Laura Toussaint, Martin Hübner, Hugo Teixeira Farinha\",\"doi\":\"10.1515/pp-2022-0197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Cytology of ascites or peritoneal washing is a routine part of staging of peritoneal metastases (PM). We aim to determine value of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC).</p><p><strong>Methods: </strong>Single-center retrospective cohort study included consecutive patients having PIPAC for PM of different primary between January 2015 and January 2020.</p><p><strong>Results: </strong>A total of 75 patients (median 63 years (IQR 51-70), 67 % female) underwent a total of 144 PIPAC. At PIPAC 1 59 % patients had positive and 41 % patients had negative cytology. Patients with negative and positive cytology only differed in terms of symptoms of ascites (16% vs. 39 % respectively, p=0.04), median ascites volume (100 vs. 0 mL, p=0.01) and median PCI (9 vs. 19, p<0.01). Among 20 patients who completed 3 PIPACs (per protocol), cytology changed in one from positive to negative, and in two from negative to positive. Median overall survival was 30.9 months in the per protocol group and 12.9 months in patients having <3 PIPACs (=0.519).</p><p><strong>Conclusions: </strong>Positive cytology under PIPAC treatment is more frequently encountered in patients with higher PCI and symptomatic ascites. Cytoversion was rarely observed and cytology status had no impact on treatment decisions in this cohort.</p>\",\"PeriodicalId\":20231,\"journal\":{\"name\":\"Pleura and Peritoneum\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249751/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pleura and Peritoneum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/pp-2022-0197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pleura and Peritoneum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/pp-2022-0197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:腹水或腹膜冲洗细胞学检查是腹膜转移(PM)分期的常规部分。我们的目的是确定细胞学在接受加压腹腔内气溶胶化疗(PIPAC)的患者中的价值。方法:单中心回顾性队列研究,纳入2015年1月至2020年1月期间连续接受PIPAC治疗不同原发PM的患者。结果:共有75例患者(中位年龄63岁(IQR 51-70), 67% %为女性)接受了144次PIPAC。在PIPAC 1时,59 %的患者细胞学阳性,41 %的患者细胞学阴性。细胞学阴性和阳性患者仅在腹水症状(分别为16% vs. 39% %,p=0.04)、腹水中位体积(100 vs. mL, p=0.01)和PCI中位(9 vs. 19, p)方面存在差异。结论:PIPAC治疗下细胞学阳性更常出现在PCI较高且有症状的腹水患者中。在这个队列中,很少观察到细胞版本,细胞学状态对治疗决策没有影响。
The role of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis.
Objectives: Cytology of ascites or peritoneal washing is a routine part of staging of peritoneal metastases (PM). We aim to determine value of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Methods: Single-center retrospective cohort study included consecutive patients having PIPAC for PM of different primary between January 2015 and January 2020.
Results: A total of 75 patients (median 63 years (IQR 51-70), 67 % female) underwent a total of 144 PIPAC. At PIPAC 1 59 % patients had positive and 41 % patients had negative cytology. Patients with negative and positive cytology only differed in terms of symptoms of ascites (16% vs. 39 % respectively, p=0.04), median ascites volume (100 vs. 0 mL, p=0.01) and median PCI (9 vs. 19, p<0.01). Among 20 patients who completed 3 PIPACs (per protocol), cytology changed in one from positive to negative, and in two from negative to positive. Median overall survival was 30.9 months in the per protocol group and 12.9 months in patients having <3 PIPACs (=0.519).
Conclusions: Positive cytology under PIPAC treatment is more frequently encountered in patients with higher PCI and symptomatic ascites. Cytoversion was rarely observed and cytology status had no impact on treatment decisions in this cohort.